These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26552422)

  • 21. Mitochondrial UQCRB regulates VEGFR2 signaling in endothelial cells.
    Jung HJ; Kim Y; Chang J; Kang SW; Kim JH; Kwon HJ
    J Mol Med (Berl); 2013 Sep; 91(9):1117-28. PubMed ID: 23708980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.
    Papadopoulos N; Martin J; Ruan Q; Rafique A; Rosconi MP; Shi E; Pyles EA; Yancopoulos GD; Stahl N; Wiegand SJ
    Angiogenesis; 2012 Jun; 15(2):171-85. PubMed ID: 22302382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel synthetic small molecule YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling.
    Liu Y; He Y; Yang F; Cong X; Wang J; Peng S; Gao D; Wang W; Lan L; Ying X; Liu M; Chen Y; Yi Z
    Sci China Life Sci; 2017 Feb; 60(2):202-214. PubMed ID: 28194552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Oncotarget; 2016 Sep; 7(39):63124-63137. PubMed ID: 27517319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Andrographolide inhibits tumor angiogenesis via blocking VEGFA/VEGFR2-MAPKs signaling cascade.
    Shen K; Ji L; Lu B; Xu C; Gong C; Morahan G; Wang Z
    Chem Biol Interact; 2014 Jul; 218():99-106. PubMed ID: 24814888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activating CD137 Signaling Promotes Sprouting Angiogenesis via Increased VEGFA Secretion and the VEGFR2/Akt/eNOS Pathway.
    Li B; Zhang Y; Yin R; Zhong W; Chen R; Yan J
    Mediators Inflamm; 2020; 2020():1649453. PubMed ID: 33162828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppression of angiogenesis and tumor growth by recombinant T4 phages displaying extracellular domain of vascular endothelial growth factor receptor 2.
    Zuo S; Dai G; Wang L; Wen Y; Huang Z; Yang W; Ma W; Ren X
    Arch Virol; 2019 Jan; 164(1):69-82. PubMed ID: 30259141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Production of neutralizing monoclonal antibody against human vascular endothelial growth factor receptor II.
    Li R; Xiong DS; Shao XF; Liu J; Xu YF; Xu YS; Liu HZ; Zhu ZP; Yang CZ
    Acta Pharmacol Sin; 2004 Oct; 25(10):1292-8. PubMed ID: 15456530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cultivated Orostachys japonicus extract inhibits VEGF-induced angiogenesis via regulation of VEGFR2 signaling pathway in vitro and in vivo.
    Cho HD; Lee KW; Won YS; Kim JH; Seo KI
    J Ethnopharmacol; 2020 Jun; 256():112664. PubMed ID: 32045685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling.
    Gao J; Hu H; Wang X
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1007-1015. PubMed ID: 30887179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis.
    Lee WS; Pyun BJ; Kim SW; Shim SR; Nam JR; Yoo JY; Jin Y; Jin J; Kwon YG; Yun CO; Nam DH; Oh K; Lee DS; Lee SH; Yoo JS
    MAbs; 2015; 7(5):957-68. PubMed ID: 25942475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo.
    Mashima T; Wakatsuki T; Kawata N; Jang MK; Nagamori A; Yoshida H; Nakamura K; Migita T; Seimiya H; Yamaguchi K
    Sci Rep; 2021 Jul; 11(1):15125. PubMed ID: 34302038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Curcumin inhibits angiogenesis and improves defective hematopoiesis induced by tumor-derived VEGF in tumor model through modulating VEGF-VEGFR2 signaling pathway.
    Fu Z; Chen X; Guan S; Yan Y; Lin H; Hua ZC
    Oncotarget; 2015 Aug; 6(23):19469-82. PubMed ID: 26254223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.
    Bi YL; Mi PY; Zhao SJ; Pan HM; Li HJ; Liu F; Shao LR; Zhang HF; Zhang P; Jiang SL
    Int J Mol Med; 2017 May; 39(5):1255-1261. PubMed ID: 28358414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tylophorine, a phenanthraindolizidine alkaloid isolated from Tylophora indica exerts antiangiogenic and antitumor activity by targeting vascular endothelial growth factor receptor 2-mediated angiogenesis.
    Saraswati S; Kanaujia PK; Kumar S; Kumar R; Alhaider AA
    Mol Cancer; 2013 Jul; 12():82. PubMed ID: 23895055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel multi-targeted inhibitors suppress ocular neovascularization by regulating unique gene sets.
    Yin X; Lin X; Ren X; Yu B; Liu L; Ye Z; Chen Q; Lee C; Lu W; Yu D; Li X
    Pharmacol Res; 2019 Aug; 146():104277. PubMed ID: 31112749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The extract of Polygoni Cuspidati Rhizoma et Radix suppresses the vascular endothelial growth factor-induced angiogenesis.
    Hu WH; Chan GK; Lou JS; Wu QY; Wang HY; Duan R; Cheng MY; Dong TT; Tsim KW
    Phytomedicine; 2018 Mar; 42():135-143. PubMed ID: 29655679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of a drug-targetable allosteric site regulating vascular endothelial growth factor signaling.
    Thieltges KM; Avramovic D; Piscitelli CL; Markovic-Mueller S; Binz HK; Ballmer-Hofer K
    Angiogenesis; 2018 Aug; 21(3):533-543. PubMed ID: 29502220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Xia Y; Song X; Li D; Ye T; Xu Y; Lin H; Meng N; Li G; Deng S; Zhang S; Liu L; Zhu Y; Zeng J; Lei Q; Pan Y; Wei Y; Zhao Y; Yu L
    Sci Rep; 2014 Aug; 4():6031. PubMed ID: 25112436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway.
    Ding Q; Tian XG; Li Y; Wang QZ; Zhang CQ
    World J Gastroenterol; 2015 Aug; 21(32):9566-76. PubMed ID: 26327764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.